371970
HA 1077, Dihydrochloride
A cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties.
别名:
HA 1077, Dihydrochloride, Fasudil, (5-Isoquinolinesulfonyl)homopiperazine, 2HCl, PKG Inhibitor VII
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C14H17N3O2S · 2HCl
化学文摘社编号:
分子量:
364.29
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
产品名称
HA 1077, Dihydrochloride, A cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties.
SMILES string
[S](=O)(=O)(N3CCNCCC3)c1c2c(cncc2)ccc1
InChI
1S/C14H17N3O2S/c18-20(19,17-9-2-6-15-8-10-17)14-4-1-3-12-11-16-7-5-13(12)14/h1,3-5,7,11,15H,2,6,8-10H2
InChI key
NGOGFTYYXHNFQH-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
water: 1 mg/mL
shipped in
ambient
storage temp.
2-8°C
Quality Level
General description
A cell-permeable, reversible, and ATP-competitive Ca2+ antagonist with anti-vasospastic properties. Inhibits protein kinase A (Ki = 1.6 µM), protein kinase G (Ki = 1.6 µM), and myosin light chain kinase (Ki = 3.6 µM). Also reported to potently inhibit Rho-associated kinase (ROCK; IC50 = 10.7 µM). Prevents apoptosis and enhances the survival and cloning efficiency of dissociated hES cells without affecting their pluripotency.
Other Notes
Watanabe, K., et al. 2007. Nature Biotech.25, 681.
Swärd, K., et al. 2000. J. Physiol.522, 33.
Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.
Seto, M., et al. 1991. Eur. J. Pharmacol.195, 267.
Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther.259, 738.
Asano, T., et al. 1990. Eur. J. Pharmacol.190, 365.
Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun.171, 1182.
Asano, T., et al. 1989. Br. J. Pharmacol. 98,1091.
Swärd, K., et al. 2000. J. Physiol.522, 33.
Takizawa, S., et al. 1993. Eur. J. Pharmacol. 250, 431.
Seto, M., et al. 1991. Eur. J. Pharmacol.195, 267.
Shirotani, M., et al. 1991. J. Pharmacol. Exp. Ther.259, 738.
Asano, T., et al. 1990. Eur. J. Pharmacol.190, 365.
Sasaki, Y., and Sasaki, Y. 1990. Biochem. Biophys. Res. Commun.171, 1182.
Asano, T., et al. 1989. Br. J. Pharmacol. 98,1091.
Preparation Note
Following reconstitution, refrigerate (4°C). Aqueous stock solutions are stable for up to 6 months at 4°C.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PKA
PKA
Product competes with ATP.
Reversible: yes
Target IC50: 10.7 µM inhibiting Rho-associated kinase (ROCK)
Target Ki: .6 µM, 1.6 µM, 36 µM, inhibiting protein kinase A, protein kinase G, myosin light chain kinase, respectively
Disclaimer
Toxicity: Harmful (C)
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持